#10: The Machine: Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
Plan to Include Refocusing of Operations and Workforce... |
April 14, 2008
12:18:24 AM |
#9: The Machine: Keryx Biopharmaceuticals to Present at JPMorgan Healthcare Conference
NEW YORK, Jan. 3 /PRNewswire-FirstCall/ -- Keryx... |
January 18, 2008
05:28:11 PM |
#8: FastFun: Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Dr. Paul Richardson presents Phase 1 results demonstrating clinical... |
December 16, 2007
06:50:50 PM |
#7: FastFun: DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program
'Room Temp' Technology Builds on Consumer Appeal and Tactical Importance... |
December 16, 2007
06:50:05 PM |
#6: FastFun: Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Data on Perifosine in the Treatment of Patients with Relapsed/Refractory... |
December 7, 2007
07:09:11 PM |
#5: FastFun: Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
No Safety Concerns Raised
Sulodexide Phase 3 study to continue without... |
December 7, 2007
07:04:08 PM |
#4: FastFun: Re: Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
I wonder if this is "fast tracked" . I hope it passes the FDA ASAP |
November 30, 2007
11:41:49 AM |
#3: FastFun: Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
Oral Presentation by Dr. Robert Figlin Highlights Phase 2 Data Showing... |
November 26, 2007
08:34:21 PM |
#2: FastFun: Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
Deal Includes up to $100MM in License Fees and Potential Milestone... |
October 15, 2007
11:54:18 PM |
#1: Jason: KERX, Keryx Biopharmaceuticals to Present at The Bank of America 2007 Health Care Conference
Presentation Scheduled for Wednesday, May 30th at 11:20am PT
Keryx... |
June 3, 2007
08:53:23 PM |
| 
| 
| 
| 
| 
| 
